Dr. Thomas Rennie, M.D.
What this data tells you about Dr. Rennie
Dr. Thomas Rennie is a rheumatology in San Antonio, TX, with 20 years in practice. Based on federal Medicare data, Dr. Rennie performed 99,175 Medicare services across 3,461 unique beneficiaries.
Between the years covered by Open Payments, Dr. Rennie received a total of $118,580 from 43 pharmaceutical and/or device companies across 869 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Rennie is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 31,400 | $4 | $19 |
| Tocilizumab injection (Actemra) | 19,714 | $5 | $17 |
| Golimumab infusion (Simponi Aria) | 19,383 | $10 | $48 |
| Abatacept infusion (Orencia) | 11,850 | $33 | $134 |
| Denosumab injection (Prolia/Xgeva) | 5,040 | $18 | $42 |
| Infliximab infusion (Remicade) | 2,672 | $26 | $114 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2,636 | $30 | $119 |
| Office visit, established patient (30-39 min) | 876 | $86 | $253 |
| Comprehensive metabolic blood panel | 745 | $10 | $26 |
| Complete blood count (CBC) with differential | 677 | $8 | $20 |
| C-reactive protein test (inflammation marker) | 558 | $5 | $14 |
| Measurement of antibody for assessment of autoimmune disorder, any method | 454 | $17 | $44 |
| Administration of chemotherapy into vein, 1 hour or less | 420 | $98 | $399 |
| Sed rate test (inflammation marker) | 290 | $3 | $6 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 241 | $56 | $222 |
| Measurement of complement (immune system proteins), antigen, | 194 | $12 | $29 |
| Analysis of substance using immunoassay technique, multiple step method | 188 | $11 | $28 |
| Office visit, established patient (20-29 min) | 187 | $64 | $166 |
| Administration of chemotherapy into vein, each additional hour | 137 | $21 | $85 |
| Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | 134 | $101 | $311 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 130 | $90 | $265 |
| Measurement of dna antibody, native or double stranded | 129 | $13 | $35 |
| Cardiolipin antibody (tissue antibody) measurement | 120 | $25 | $63 |
| Beta 2 glycoprotein 1 antibody (autoantibody) measurement | 117 | $25 | $63 |
| Rheumatoid factor level | 94 | $6 | $15 |
| Screening test for autoimmune disorder | 93 | $12 | $29 |
| Injection, methylprednisolone acetate, 40 mg | 92 | $6 | $15 |
| Measurement of dna antibody, single stranded | 85 | $12 | $29 |
| Uric acid level test | 80 | $4 | $12 |
| Vitamin D level test | 67 | $28 | $72 |
| New patient office visit (45-59 min) | 67 | $123 | $497 |
| Joint injection, major joint | 59 | $49 | $118 |
| Thyroid stimulating hormone (TSH) test | 50 | $16 | $42 |
| Measurement of antibody for rheumatoid arthritis assessment | 34 | $13 | $32 |
| Injection of additional new drug or substance into vein | 30 | $12 | $47 |
| Creatine kinase (cardiac enzyme) level, total | 29 | $6 | $17 |
| Flu vaccine, quadrivalent | 26 | $74 | $75 |
| Flu vaccine administration | 25 | $30 | $61 |
| Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | 20 | $282 | $299 |
| Pneumonia vaccine administration | 16 | $30 | $61 |
| Injection, methylprednisolone acetate, 80 mg | 16 | $8 | $28 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (67%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 7% for rheumatology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Rennie is a mixed practice specialist, with above-average Medicare volume (top 15% in TX), and high industry engagement (speaking/promotional, top 7%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Rennie experienced with certolizumab injection (cimzia)?
Does Dr. Rennie receive payments from pharmaceutical companies?
How do Dr. Rennie's costs compare to other rheumatologys in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology